The Senate has started its first official committee investigation into the price increase of EpiPen, a life-saving allergy drug that has a $600 price tag.

The Permanent Subcommittee on Investigations will look into EpiPen maker Mylan Pharmaceuticals’ pricing and competition practices, according to Sens. Rob Portman, R-Ohio, and Claire McCaskill, D-Mo., the chairman and top Democrat on the committee, respectively.

Recommended Stories

Senators seek probe of EpiPen rebates

What top Democrats have in mind for healthcare

FDA approves first generic competitor for EpiPen